Sangeetha Palakurthi

Vice President, In Vivo Pharmacology

Sangeetha joined Elstar Therapeutics with extensive oncology drug discovery and preclinical development experience within both pharmaceutical and academic settings. Most recently, she served as the head of the Cancer Biology and Pharmacology team at the Belfer Center for Applied Cancer Science at the  Dana-Farber Cancer Institute. Her responsibilities there included design and execution of a portfolio of industry and academic investigator sponsored translational pharmacology projects of targeted agents and immunotherapies to enable better clinical trial design decisions. Prior to that, Sangeetha led and supported oncology drug discovery programs from target identification to candidate drug nomination at AstraZeneca. Her research included design of strategies and execution of rationale-driven “proof of concept” studies to guide translation of right drugs to the right patients.

Sangeetha received her Ph.D. in Biochemistry from the Osmania University in India and worked as a Scientist at Dr. Reddy’s Laboratories prior to her postdoctoral fellowship at Harvard Medical School.

bio pic

Madan Katragadda

Vice President, Antibody Discovery and Protein Engineering

Madan Katragadda heads Antibody Discovery and Protein Engineering group, which is responsible for, discovering, designing and delivering Elstar’s biotherapeutic candidates with optimal biophysical and manufacturable properties. He has more than 15 years of experience discovering and developing a wide range of biotherapeutic modalities spanning peptides, fusion proteins, Antibody-drug-conjugates and multi-specific Antibodies. His first foray into biotherapeutics started with discovery of peptide-based complement inhibitors during his postdoc tenure at the University of Pennsylvania. His work led to out-licensing of an anti-C3 peptide to Apellis pharmaceuticals who is currently testing it in several inflammatory diseases in Phase II.

Prior to joining Elstar, Madan held positions with increasing responsibility at Pfizer, where he led an Antibody Engineering group, built cross-functional teams to deliver on innovative ideas and new technology platforms and managed several biotherapeutic projects through internal and external collaborations. He delivered several biotherapeutic candidates to treat Inflammatory and Oncology indications for preclinical/clinical development. His work at the University of Pennsylvania and Pfizer resulted in several patents and publications.

Madan holds a Ph.D. in Biochemistry from the University of Connecticut and completed his postdoctoral training at the University of Pennsylvania.